Amgen And AstraZeneca Tout Fresh Tezepelumab Data
TSLP Inhibitor Impresses For Nasal Polyps
Recently-submitted tezepelumab reduced the annualized asthma exacerbation rate by 86% in a subgroup of patients with severe, uncontrolled asthma and nasal polyps, according to data presented at the European Respiratory Society congress.
